如果您要报告不良事件或产品投诉,请拨打礼来客户服务中心热线400-828-2059(手机),800-828-2059(座机)

return icon返回

唯择®(阿贝西利片)

本网站提供的产品说明书及使用说明均为最新批准版本。
20%作为Ki-67的临界值的基本原理是什么?
阿贝西利;截止;高;低;诊断;20%;在20%;

CN_cFAQ_ABE089H_Ki67_CUTOFF_VALUE
CN_cFAQ_ABE089H_Ki67_CUTOFF_VALUEzh-CN

回复

截止值是由历史数据和编写 monarchE 协议时的圣加仑共识决定的。

详细信息

在针对高风险、淋巴结阳性、激素受体阳性、人表皮生长因子受体 2 阴性、早期乳腺癌患者开展的阿贝西利联合标准辅助内分泌治疗 (ET) 对比单用标准辅助ET治疗的 monarchE 随机、开放标签、3 期研究中,使用 20% 的 Ki-67 临界值鉴别 Ki-67 高表达肿瘤患者。1

在制定 monarchE 方案时,根据历史数据和 St. Gallen 共识界定临界值。1-3

虽然目前尚未就区分患者疾病复发风险高低的 Ki-67 评分形成国际共识,但一般认为 20% 左右的临界值适合用来鉴别高风险人群。2,4-7

上次审阅日期:2024年4月24日

参考文献

1Johnston SRD, Harbeck N, Hegg R, et al; monarchE Committee Members and Investigators. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987-3998. https://doi.org/10.1200/JCO.20.02514

2Vasconcelos I, Hussainzada A, Berger S, et al. The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival. Breast. 2016;29:181-185. https://doi.org/10.1016/j.breast.2016.07.016

3Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies--improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26(8):1533-1546. https://doi.org/10.1093/annonc/mdv221

4Nielsen TO, Leung SC, Rimm DL, et al. Assessment of Ki67 in breast cancer: updated recommendations form the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2020;113(7):808-819. https://doi.org/10.1093/jnci/djaa201

5Fasching PA, Gass P, Häberle L, et al. Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. Breast Cancer Res Treat. 2019;175(3):617-625. http://dx.doi.org/10.1007/s10549-019-05198-9

6Gluz O, Nitz UA, Christgen M, et al. West German study group phase III PlanB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol. 2016;34(20):2341-2349. https://doi.org/10.1200/JCO.2015.63.5383

7Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology. 2017;49(2):166-171. https://doi.org/10.1016/j.pathol.2016.11.006

相关问答(38)

通过扫描二维码

体验礼来医学网小程序

通过扫描二维码

体验礼来医学网Sina微博

mini iconsearch icon
return icon打开礼来医学网小程序